Brief: XBiotech Announces First Patient In Phase 2 Study Evaluating Patients With Atopic Dermatitis
22/05/2018 13:42
May 22 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH ANNOUNCES FIRST PATIENT IN PHASE 2 STUDY
EVALUATING
MABP1 IN PATIENTS WITH ATOPIC DERMATITIS
Source text for Eikon: ID:nGNX4FKTT
Further company coverage: XBIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke